NASDAQ:ACERAcer Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Acer Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.12 -0.13 (-4.00 %) (As of 07/7/2020 04:00 PM ET) Add Compare Share Today's Range$3.09Now: $3.12▼$3.3150-Day Range$3.07MA: $3.35▼$4.5352-Week Range$1.08Now: $3.12▼$7.25Volume155,000 shsAverage Volume152,091 shsMarket Capitalization$31.98 millionP/E RatioN/ADividend YieldN/ABeta1.81 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes three clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; and ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders, maple syrup urine disease, and osanetant for the treatment of various neuroendocrine disorders. The company was founded in 2013 and is headquartered in Newton, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.3 Analyst's Opinion Consensus RatingAcer Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.00, Acer Therapeutics has a potential upside of 220.5% from its current price of $3.12.Amount of Analyst CoverageAcer Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesAcer Therapeutics has received 280 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAcer Therapeutics has received 236 “underperform” votes. (Add your “underperform” vote.)Community SentimentAcer Therapeutics has received 54.26% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Acer Therapeutics and other stocks. Vote “Outperform” if you believe ACER will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ACER will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAcer Therapeutics does not currently pay a dividend.Dividend GrowthAcer Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Acer Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 20.10% of the stock of Acer Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 22.45% of the stock of Acer Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Acer Therapeutics are expected to grow in the coming year, from ($1.38) to ($1.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acer Therapeutics is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acer Therapeutics is -1.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcer Therapeutics has a P/B Ratio of 1.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.32 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACER Previous Symbol CUSIPN/A CIK1069308 Webwww.acertx.com Phone844-902-6100Debt Debt-to-Equity RatioN/A Current Ratio4.29 Quick Ratio4.29Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.82 per share Price / Book1.71Profitability EPS (Most Recent Fiscal Year)($2.91) Net Income$-29,420,000.00 Net MarginsN/A Return on Equity-127.41% Return on Assets-110.05%Miscellaneous Employees23 Outstanding Shares10,249,000Market Cap$31.98 million Next Earnings Date8/11/2020 (Estimated) OptionableNot Optionable NASDAQ:ACER Rates by TradingView Receive ACER News and Ratings via Email Sign-up to receive the latest news and ratings for ACER and its competitors with MarketBeat's FREE daily newsletter. Acer Therapeutics (NASDAQ:ACER) Frequently Asked Questions How has Acer Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Acer Therapeutics' stock was trading at $3.38 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ACER stock has decreased by 7.7% and is now trading at $3.12. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Acer Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acer Therapeutics in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Acer Therapeutics. When is Acer Therapeutics' next earnings date? Acer Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Acer Therapeutics. How were Acer Therapeutics' earnings last quarter? Acer Therapeutics Inc (NASDAQ:ACER) released its quarterly earnings data on Thursday, May, 14th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.40) by $0.09. View Acer Therapeutics' earnings history. What price target have analysts set for ACER? 4 brokerages have issued twelve-month price objectives for Acer Therapeutics' stock. Their forecasts range from $10.00 to $10.00. On average, they anticipate Acer Therapeutics' stock price to reach $10.00 in the next year. This suggests a possible upside of 220.5% from the stock's current price. View analysts' price targets for Acer Therapeutics. Has Acer Therapeutics been receiving favorable news coverage? News stories about ACER stock have trended negative this week, according to InfoTrie. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Acer Therapeutics earned a coverage optimism score of -2.1 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about Acer Therapeutics. Are investors shorting Acer Therapeutics? Acer Therapeutics saw a increase in short interest in June. As of June 30th, there was short interest totaling 578,500 shares, an increase of 8.6% from the June 15th total of 532,700 shares. Based on an average daily trading volume, of 208,000 shares, the short-interest ratio is presently 2.8 days. Approximately 11.3% of the company's stock are sold short. View Acer Therapeutics' Current Options Chain. Who are some of Acer Therapeutics' key competitors? Some companies that are related to Acer Therapeutics include Bellerophon Therapeutics (BLPH), ESSA Pharma (EPIX), PhaseBio Pharmaceuticals (PHAS), Sierra Oncology (SRRA), Inflarx (IFRX), Genprex (GNPX), TFF Pharmaceuticals (TFFP), Catabasis Pharmaceuticals (CATB), Gemphire Therapeutics (GEMP), Aldeyra Therapeutics (ALDX), Theratechnologies (THERF), OASMIA PHARMACE/ADR (OASM), Leap Therapeutics (LPTX), Eton Pharmaceuticals (ETON) and Conatus Pharmaceuticals (CNAT). View all competitors. What other stocks do shareholders of Acer Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Acer Therapeutics investors own include Sarepta Therapeutics (SRPT), Amarin (AMRN), Anavex Life Sciences (AVXL), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), Advanced Micro Devices (AMD), Arena Pharmaceuticals (ARNA) and Crispr Therapeutics (CRSP). Who are Acer Therapeutics' key executives? Acer Therapeutics' management team includes the following people: Mr. Christopher Schelling, Founder, Pres, CEO & Director (Age 43)Mr. Harry S. Palmin, COO & CFO (Age 49)Dr. William T. Andrews M.D., FACP, Chief Medical Officer (Age 54)Mr. Donald R. Joseph, Chief Legal Officer & Sec. (Age 65)Ms. Jeannie Kim, VP of Corp. Devel. What is Acer Therapeutics' stock symbol? Acer Therapeutics trades on the NASDAQ under the ticker symbol "ACER." How do I buy shares of Acer Therapeutics? Shares of ACER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Acer Therapeutics' stock price today? One share of ACER stock can currently be purchased for approximately $3.12. How big of a company is Acer Therapeutics? Acer Therapeutics has a market capitalization of $31.98 million. The biopharmaceutical company earns $-29,420,000.00 in net income (profit) each year or ($2.91) on an earnings per share basis. Acer Therapeutics employs 23 workers across the globe. What is Acer Therapeutics' official website? The official website for Acer Therapeutics is www.acertx.com. How can I contact Acer Therapeutics? Acer Therapeutics' mailing address is 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458. The biopharmaceutical company can be reached via phone at 844-902-6100 or via email at [email protected] This page was last updated on 7/7/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
